Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
The Top 7 Growth Stocks in Biotech
March 03, 2023
Tags
Stocks to Buy
ITOS
NASDAQ:ITOS,NASDAQ:VIR,NASDAQ:BEAM,NASDAQ:KNSA,OTCMKTS:RHHBY,NASDAQ:DVAX,NASDAQ:CMRX,NASDAQ:APVO
From InvestorPlace
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
March 03, 2023
From Benzinga
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
March 02, 2023
From Motley Fool
3 Best Growth Stocks to Buy In March
March 02, 2023
From Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
February 27, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
February 07, 2023
From Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
February 02, 2023
From Benzinga
From Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
January 19, 2023
From Benzinga
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
From Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
January 12, 2023
From Benzinga
From Benzinga
From Benzinga
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
January 02, 2023
From Motley Fool
Roche's Follicular Lymphoma Therapy Scores FDA Approval
December 23, 2022
From Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
December 22, 2022
From Benzinga
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
December 20, 2022
From InvestorPlace
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 13, 2022
From Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
December 12, 2022
From Benzinga
From Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
December 12, 2022
From Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
From Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
From Motley Fool
From Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.